Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT03842189 |
| Consolidated Lead Sponsor | Johnson & Johnson / Janssen |
| Therapeutic Condition Cohort | Rare Genetic, Women's Health, and Other |
| Clinical Trial Phase | Phase II |
| Overall Recruitment Status | COMPLETED |
| Registered Enrollment | 25 participants (ACTUAL) |
| Registered Start Date | 2018-04-05 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| UCSF Medical Center and Helen Diller Cancer Center | San Francisco, CA | Open Hospital Dossier -> |
| Columbia University Irving Medical Center | New York, NY | Open Hospital Dossier -> |
| University of Cincinnati | Cincinnati, OH | Open Hospital Dossier -> |
| Oregon Health and Science University Knight Cancer Institute | Portland, OR | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.